• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
        • NTM Lung Disease
        • Bronchiectasis
        • Pulmonary Arterial Hypertension
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • ARIKAYCE®
      • Our Programs
      • Pipeline
      • Clinical Trials
      • Our Research Team
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • May 8, 2014
    Insmed Reports First Quarter 2014 Financial Results
  • Apr 7, 2014
    Insmed to Participate in the 13th Annual Needham & Co. Healthcare Conference
  • Apr 2, 2014
    Insmed Announces Leadership Team Transitions and Appointments to Expand Support for Growth Opportunities
  • Mar 26, 2014
    Insmed Announces Results from Phase 2 Clinical Trial for Treatment Resistant Nontuberculous Mycobacterial Lung Infections
    Conference Call with Insmed Management and Clinical Trial Investigators Will be Held Today at 8:00 a.m. Eastern Time
  • Mar 25, 2014
    Insmed to Announce Results From U.S. Phase 2 Clinical Trial for Treatment Resistant Nontuberculous Mycobacteria Lung Infections
  • Mar 6, 2014
    Insmed Reports 2013 Fourth Quarter and Full Year Financial Results
  • Feb 19, 2014
    Insmed Provides Interim Update from Two-Year, Open-Label Extension Study of ARIKACE to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients
    Initial 12-Month Data Demonstrate Long-Term Safety and Durability of Effect
  • Feb 10, 2014
    ARIKACE to Receive Orphan Medicinal Product Designation in the European Union to Treat Lung Infections Caused by Nontuberculous Mycobacteria
  • Feb 4, 2014
    Insmed to Present at the Leerink Swann Global Healthcare Conference
  • Feb 4, 2014
    Insmed to Present at the Leerink Swann Global Healthcare Conference
  • Nov 5, 2013
    Insmed Reports Third Quarter 2013 Financial Results
  • Nov 1, 2013
    Insmed Appoints David W.J. McGirr to Its Board of Directors
  • Oct 23, 2013
    Insmed to Host Third Quarter 2013 Financial Results Conference Call on Tuesday, November 5, 2013
  • Oct 15, 2013
    Insmed Completes Enrollment of Phase 2 Clinical Trial of ARIKACE to Treat Nontuberculous Mycobacteria Lung Disease in U.S. and Canada
  • Sep 15, 2013
    Insmed to Present at Leerink Swann Rare Disease Roundtable
  • Sep 11, 2013
    Insmed Fortifies Global Patent Portfolio
  • Sep 4, 2013
    Insmed to Participate in the Stifel Healthcare Conference 2013
  • Aug 7, 2013
    Insmed to Participate in August Investor Conferences
  • Aug 6, 2013
    Insmed Reports Second Quarter Financial Results
  • Jul 31, 2013
    Insmed to Host Second Quarter 2013 Financial Results Conference Call on Tuesday, August 6, 2013
  • Jul 29, 2013
    Insmed Appoints Christine Pellizzari as General Counsel and Corporate Secretary
  • Jul 22, 2013
    Insmed Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares
  • Jul 17, 2013
    Insmed Announces Pricing of Public Offering of Common Stock
  • Jul 15, 2013
    Insmed Announces Proposed Public Offering of Common Stock
  • Jul 8, 2013
    Insmed to Present at the 8th Annual JMP Securities Healthcare Conference
  • Jul 1, 2013
    ARIKACE Meets Primary Endpoint of Non-Inferiority to TOBI in Phase 3 Clinical Trial in Europe and Canada to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients
    ARIKACE Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. FDA for the Treatment of Non-Tuberculous Mycobacteria Lung Infections
  • Jun 28, 2013
    Insmed to Join the Russell Global(R) and Russell 3000(R) Indexes
  • Jun 28, 2013
    Insmed to Report Top-Line Results From Phase 3 Clinical Trial of ARIKACE to Treat Pseudomonas Aeruginosa in Cystic Fibrosis
  • May 14, 2013
    Insmed Granted Key Composition of Matter Patent Allowance for ARIKACE in Europe
  • May 13, 2013
    Insmed to Present at the UBS Global Healthcare Conference
  • May 10, 2013
    Insmed to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
  • May 7, 2013
    Insmed Reports First Quarter Financial Results
  • May 1, 2013
    Insmed to Host First Quarter 2013 Financial Results Conference Call on Tuesday, May 7, 2013
  • Apr 18, 2013
    Insmed to Present at the 12th Annual Needham Healthcare Conference
  • Apr 1, 2013
    Insmed Appoints Matthew Pauls as Chief Commercial Officer
  • Mar 28, 2013
    ARIKACE Receives Orphan Drug Designation for Treating Infections Caused by Non-Tuberculous Mycobacteria
  • Mar 27, 2013
    Insmed to Present at Future Leaders in the Biotech Industry Conference
  • Mar 18, 2013
    Insmed Reports Fourth Quarter and Full Year 2012 Financial Results
  • Mar 11, 2013
    Insmed to Host Fourth Quarter and Full Year 2012 Financial Results Conference Call on Monday, March 18, 2013
  • Feb 26, 2013
    Insmed to Present at Two Upcoming Investor Conferences
  • Feb 6, 2013
    Insmed to Present at Two Upcoming Healthcare Investor Conferences
  • Dec 13, 2012
    Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference
  • Nov 13, 2012
    Insmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections Has Completed Target Enrollment
  • Nov 12, 2012
    Insmed To Present At Two Upcoming Investor Conferences
  • Nov 7, 2012
    Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
  • Nov 7, 2012
    Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2012
  • Oct 24, 2012
    Insmed to Host 2012 Third Quarter Earnings Conference Call
  • Sep 28, 2012
    Insmed Announces Pricing of Approximately $26 Million Direct Public Offering
  • Aug 30, 2012
    Insmed to Present at Stifel Nicolaus 2012 Healthcare Conference
  • Aug 14, 2012
    Insmed to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference
Show 5102550100 per page
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 13
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
      • NTM Lung Disease
      • Bronchiectasis
      • Pulmonary Arterial Hypertension
    • Resources
    • Patient Access
  • Our Science
    • ARIKAYCE®
    • Our Programs
    • Pipeline
    • Clinical Trials
    • Our Research Team
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2022 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
      • NTM Lung Disease
      • Bronchiectasis
      • Pulmonary Arterial Hypertension
    • Resources
    • Patient Access
  • Science
    • ARIKAYCE®
    • Our Programs
    • Pipeline
    • Clinical Trials
    • Our Research Team
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2022 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy